Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
|Videos|November 5, 2021
Physicians Might Under Dose ACEs and ARBs Due to Acute Kidney Injury
Chi Chu, MD, an assistant professor in the division of nephrology at the University of California San Francisco, why providers might under dose ACE and ARB treatments for proteinuria.
Advertisement
In a Pharmacy Times® interview, Chi Chu, MD, an assistant professor in the division of nephrology at the University of California San Francisco, spoke about his 2021 ASN Kidney Week presentation on the submaximal dose of angiotensin converting enzyme (ACE) inhibitor and angiotensin II receptor blockers (ARB) for individuals with proteinuria.
He discussed why providers might under dose ACE and ARB treatments for proteinuria.
Advertisement
Related to this article
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
IRAKLIA shows isatuximab OBI boosts comfort and satisfaction vs IV in multiple myeloma, enabling fast at-home dosing with strong completion.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Long-term CASSIOPEIA Registry results show that daratumumab maintenance supports sustained minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma.
A phase 1/2 analysis found rapid, deep responses with mezigdomide plus elranatamab in patients with relapsed or refractory multiple myeloma, but the small cohort and limited follow-up require cautious interpretation.
At NEIAP 2026, Kelsey Norman, PharmD, walked through how VESALIUS-CV, Lp(a)HORIZON, and CKM guidelines change pharmacist-led lipid care.
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
FDA Approves Belzutifan Plus Lenvatinib for Advanced Renal Cell Carcinoma After Immunotherapy
4
Harnessing the Gut Microbiome for Enhanced CAR T Cell Therapy
5